Glasgow-based engineering company MR CoilTech has secured a prestigious grant for its NEUROQUANT project, a pioneering study on Alzheimer’s disease that utilises the custom-built 7T MRI neurovascular coil developed as part of the University of Glasgow-led Living Laboratory for Precision Medicine programme. 

The two-year study is jointly funded by Innovate UK and InnoSuisse, and is being delivered by MR CoilTech in collaboration with UK-based Gold Standard Phantoms, and Skope Magnetic Resonance Technologies and Hopitaux Universitaires Geneve in Switzerland. 

The NEUROQUANT project will harness the new neurovascular coil to enhance Alzheimer’s disease diagnosis, prognosis, and therapy monitoring. Given the global health challenge posed by Alzheimer’s, this study will play a key role in advancing diagnostic precision and improving patient outcomes. 

MR CoilTech design, test and manufacture specialised radiofrequency (RF) coils, the devices responsible for generating and receiving the signal required to produce images of the body, for new generation, ultra-high field MRI scanners. They are an industry partner in the Living Laboratory – an internationally leading programme supported by UKRI Strength in Places Funding.

The neurovascular coil is the second in a series of body-part-specific 7T MRI coils that are being constructed and validated with MR CoilTech as part of the Living Laboratory’s Coil Development project, starting with academic prototype coils tested on the 7T MRI scanner within ICE. A head coil has already been developed for clinical use, with pelvic and spinal imaging coils next in line.

The enhanced imaging power generated by these new coils will ultimately extend the utility of 7T MRI for diagnosing and monitoring a wide range of diseases, including Alzheimer’s.

First published: 22 January 2025

<< News & Events


The Living Laboratory for Precision Medicine

MR CoilTech